glp-1 drug news Weight-loss, diabetes drugs linked to vision problems in small study Novo's Wegovy becomes first GLP-1
Description
The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese adults
The GLP1-RAs vs sodium-glucose cotransporter-2 (SGLT-2) inhibitors cohort included new users of GLP-1 RAs (n=83,464) or SGLT-2 inhibitors (n=78,366), and the GLP1-RAs vs dipeptidyl peptidase-4 (DPP-4) inhibitors cohort included new users of GLP-1 RAs (n=108,322) or DPP-4 inhibitors (n=55,411)
Do GLP-1 patches really work for weight loss and diabetes
As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy
They might
